Finecure has several accolades to its credit including the “Arch of Europe Award” 2012 and Assocham India Business Excellence Award 2013 The Company is poised for vertical growth, with modern facilities, skills and knowhow and resources that are at par with the best in the country. The company has state-of-the-art manufacturing facilities and maintains all specific set of standards mandated by the Food and Drug Administration (FDA). The company is certified for WHO GMP, ISO 9001, ISO 22001, ISO 14001, OHSAS 18001 quality systems towards High Product Quality Assurance, Environment Management System, Occupational Health and safety.
The Company is CRISIL 1A rated towards "Highest Performance Capability" and "High Financial Strength" and is maintaining a Double digit growth rate. Finecure has shown an annual growth of 50% in the last fiscal year and 36% compounded annual growth (CAGR) indicating company’s strategic policy implementation and performance strength.
The company continues to explore avenues of growth and development through SBU’s focusing on the Domestic and Export Markets. Backed by a determined administration, a resolute workforce, state-of-the-art work environment, an effective R&D and F&D department and strong ethical values, the company is poised to take significant strides towards further progress and accomplishment Finecure runs on principles of quality management systems as per EFQM guided by its mission, vision, values and ethics which act as role models. The company ensures Environment Safety, Health and Hazard Risk Management and CSR. Finecure has received many honours, awards and testimonials, from prestigious organizations like FICCI, ASSOCHAM, IDMA and Pharmexcil acknowledging their excellence in the pharmaceutical market.
Since inception, superlative production values stemming from Finecure’s Commitment to quality in pharma products earned us a global acclaim. The company is PIC/S compliant.
The company is moving towards a long term goal of discovery, development, manufacture, marketing and sales of novel drugs.